Antibacterial activity and therapeutic efficacy of FI-P_RP_RP_L-5, a cationic amphiphilic polyproline helix, in a mouse model of staphylococcal skin infection

Shankar Thangamani¹Manish Nepal²Jean Chmielewski²Mohamed N Seleem¹

¹Department of Comparative Pathobiology, Purdue University College of Veterinary Medicine, West Lafayette, IN, USA; ²Department of Chemistry, Purdue University, West Lafayette, IN, USA

Abstract: The antibacterial activities and therapeutic efficacy of the cationic, unnatural proline-rich peptide FI-P_RP_RP_L-5 were evaluated against multidrug-resistant *Staphylococcus aureus* in a mouse model of skin infection. FI-P_RP_RP_L-5 showed potent activity against all clinical isolates of *S. aureus* tested, including methicillin- and vancomycin-resistant *S. aureus* (MRSA and VRSA, respectively). FI-P_RP_RP_L-5 was also superior in clearing established in vitro biofilms of *S. aureus* and *Staphylococcus epidermidis*, compared with the established antimicrobials mupirocin and vancomycin. Additionally, topical treatment of an MRSA-infected wound with FI-P_RP_RP_L-5 enhanced wound closure and significantly reduced bacterial load. Finally, 0.5% FI-P_RP_RP_L-5 significantly reduced the levels of the inflammatory cytokines tumor necrosis factor- α (TNF- α), interleukin-6 (IL-6), and interleukin-1 beta (IL-1 β) in wounds induced by MRSA skin infection. In conclusion, the results of this study suggest the potential application of FI-P_RP_RP_L-5 in the treatment of staphylococcal skin infections.

Keywords: antimicrobial peptides, *Staphylococcus aureus*, biofilms, anti-inflammatory, skin infection

Introduction

Staphylococcus aureus, a common and virulent pathogen, is the leading cause of nosocomial wound infections.¹⁻³ Virulence factors, toxins, and exoproteins secreted by multidrug-resistant strains of *S. aureus* play a major role in evading host immune response, leading to persistent infection, prolonged inflammation, and delayed wound healing.⁴⁻⁶ Furthermore, staphylococcal skin infections often lead to invasive infections that ultimately result in septicemia.^{7,8} Recently, superficial cutaneous bacterial infections caused by biofilm-producing *Staphylococci* multidrug-resistant strains have become an emerging clinical problem often associated with treatment failure, even with topical drugs of choice, such as mupirocin and fusidic acid.⁹⁻¹¹ Hence, there is an urgent need for novel antimicrobials that can be used to treat cutaneous staphylococcal infections successfully and overcome the antibiotic resistance associated with biofilm-producing *Staphylococci* spp. One potential alternative approach is the development of antimicrobial peptides as novel therapeutic agents.¹² Antimicrobial peptides with anti-inflammatory properties in addition to potent, broad-spectrum antimicrobial activity might form a promising approach to the treatment of staphylococcal skin infections.^{12,13}

Correspondence: Mohamed N Seleem
Department of Comparative Pathobiology, Purdue University College of Veterinary Medicine, 625 Harrison St, West Lafayette, IN, 47907, USA
Tel +1 765 494 0763
Fax +1 765 496 2627
Email mseleem@purdue.edu

Table 1 Antimicrobial activity of FI-P_RP_RP_L-5 against clinical isolates of *Staphylococcus aureus*

Staphylococcus strain name		Origin	Molecular typing		Phenotypic properties	MIC/MBC (μM)
NARSA ID	Alternate designation		SCCmec type	spa type		
NRS382	USA100	US	II	TJMBMDMGMK	Resistant to ciprofloxacin, clindamycin, erythromycin, and methicillin	16/16
NRS383	USA200	US	II	WGKAKAOMQQQ	Resistant to ciprofloxacin, clindamycin, erythromycin, gentamicin, and methicillin	16/16
NRS384	USA300	US	IV	YHGFMQBLO	Resistant to erythromycin, methicillin, and tetracycline	16/16
NRS386	USA700	US	IV	UJGFMGGM	Resistant to erythromycin and methicillin	16/16
NRS107	—	US	—	YHGGFMBQBLQ	Resistant to methicillin and mupirocin	16/16
VRSA5	—	US	II	TJMBMDMGMK	Resistant to vancomycin	8/8
<i>S. aureus</i>	—	—	—	—	Biofilm-producing clinical isolate	16/16
ATCC 6538	—	—	—	—	—	—
<i>S. epidermidis</i>	NRS-101	US	—	—	Biofilm-producing clinical isolate; resistant to methicillin and gentamicin	8/16

Abbreviations: NARSA, Network on Antimicrobial Resistance in *Staphylococcus aureus*; ID, identification; MIC, minimum inhibitory concentration; MBC, minimum bactericidal concentration; ATCC, American Type Culture Collection; spa, staphylococcal protein A; SCC, staphylococcal cassette chromosome; —, not available.

Mice infection

Murine MRSA skin infection study was performed, as described before.²⁰ Briefly, groups of mice (five mice per group) were infected intradermally with 1.65×10^8 colony-forming units of MRSA USA300 and were left for 48 hours before an open wound formed at the injection site. Mice were divided into three groups, and each group of mice was treated with either 0.5% FI-P_RP_RP_L-5, 2% mupirocin, or vehicle alone (petroleum jelly). All groups of mice were treated once a day for 4 days. Exactly 24 hours after the last treatment, mice were euthanized, and the area around the wound was slightly swabbed with 70% ethanol. Wound area (1 cm²) was precisely excised, homogenized, and plated onto mannitol salt agar plates to count viable bacterial colony-forming units. The animal care and all experiments were performed in accordance with the guidelines approved by Purdue University Animal Care and Use Committee (PACUC).

Quantifying inflammatory cytokines

Skin homogenates obtained from the MRSA-infected wounds were centrifuged, and the supernatants were used to quantify the levels of inflammatory cytokines, including tumor necrosis factor alpha (TNF-α), interleukin-6 (IL-6), interleukin-1 beta (IL-1β), and monocyte chemoattractant protein-1. Duo-set enzyme-linked immunosorbent assay kits (R&D Systems, Inc, Minneapolis, MN, USA) were employed to detect cytokine levels, and the experiment was carried out using the manufacturer's protocol.²¹

Statistical analyses

Statistical analyses were assessed by Graph Pad Prism 6.0 (Graph Pad Software, La Jolla, CA, USA). *P*-values were calculated by the two-tailed Student's *t*-test. *P*-values of <0.05 were considered as significant.

Results and discussion

FI-P_RP_RP_L-5 has potent activity against clinical isolates of *S. aureus*

The antimicrobial activity of FI-P_RP_RP_L-5 was evaluated against a panel of clinical *S. aureus* isolates (Table 1). FI-P_RP_RP_L-5 showed bactericidal activity against this panel of multidrug-resistant *S. aureus* strains that are resistant to methicillin, gentamicin, mupirocin, vancomycin, clindamycin, and erythromycin. FI-P_RP_RP_L-5 was also active against MRSA USA300, which has been linked to the majority of skin and soft tissue infections present in the US.²² FI-P_RP_RP_L-5 showed bactericidal activity against all tested strains of *S. aureus*, regardless of their antibiotic resistance, with MICs ranging from 8–16 μM (Table 1).

FI-P_RP_RP_L-5 is effective in clearing preformed biofilms

Bacterial biofilms play a major role in bacterial resistance. They often impede antimicrobial penetration, leading to treatment failures that increase the rate of emergence of bacterial resistance.^{9,23} Therefore, we evaluated the effect of FI-P_RP_RP_L-5 on preformed biofilms. As shown in Figure 2, treatment with FI-P_RP_RP_L-5 and control antibiotics (mupirocin and vancomycin) significantly reduced the masses of preformed biofilms generated by biofilm-forming strains of *S. aureus* and *S. epidermidis*. FI-P_RP_RP_L-5 was found to be significantly superior to mupirocin and vancomycin in reducing biofilm mass. FI-P_RP_RP_L-5, at twice the MIC reduced the mass of the *S. aureus* biofilm, by more than 50%. Mupirocin and vancomycin reduced the mass of the established biofilm by only 25%, even at 32 times their respective MICs (Figure 2A). Similarly, FI-P_RP_RP_L-5, at

Figure 2 The effects of FI-P_RP_RP_L-5 and antibiotics (mupirocin and vancomycin) on established biofilms of *Staphylococcus aureus* (A) and *Staphylococcus epidermidis* (B). The established biofilms treated with control antibiotics or FI-P_RP_RP_L-5 were stained with crystal violet. Intensity of crystal violet was measured using a spectrophotometer.

Notes: The results are presented as means ± SD from two independent experiments (n=3). **#P-values of ≤0.05 are considered as significant. **Treatment groups compared to controls; #FI-P_RP_RP_L-5 as compared to antibiotics.

Abbreviations: MIC, minimum inhibitory concentration; SD, standard deviation.

a concentration 16 times its MIC, significantly reduced the mass of a pre-established *S. epidermidis* biofilm by approximately 40%, whereas mupirocin and vancomycin, at 128 times their respective MICs, reduced the mass of the biofilm by approximately 10% and 20%, respectively (Figure 2B). These results suggest that FI-P_RP_RP_L-5 exhibits substantially more potent activity against staphylococcal biofilms than the traditional antimicrobials mupirocin and vancomycin.

FI-P_RP_RP_L-5 enhances wound closure and reduces bacterial load

Confident in the broad-spectrum antimicrobial activity and potent antibiofilm properties of FI-P_RP_RP_L-5, we

tested its in vivo anti-staphylococcal activity in a mouse model of MRSA skin infection. Three groups of BALB/C mice were intradermally infected with MRSA USA300. The open wound that formed 2 days after infection was treated topically with vehicle alone (petroleum jelly), 2% mupirocin, or 0.5% FI-P_RP_RP_L-5 once a day for 4 days. As shown in Figure 3A, topical treatment with 0.5% FI-P_RP_RP_L-5 for 4 days considerably enhanced the rate of wound closure compared with the control and 2% mupirocin treatment groups. However, the mean bacterial count was significantly reduced in both the mupirocin and FI-P_RP_RP_L-5 treatment groups, compared with the control group ($P \leq 0.05$). As shown in Figure 3B, the groups treated with 2% mupirocin had the highest reduction in

Figure 3 Efficacy of treatment of MRSA skin lesions with 0.5% FI-P_RP_RP_L-5, 2% mupirocin, and petroleum jelly (negative control) once a day for 4 days. (A) Representative macroscopic views of wounds before and after treatment with control, 0.5% FI-P_RP_RP_L-5, and 2% mupirocin. (B) Percent bacterial reduction after treatment with peptide and control antibiotics compared to control.

Notes: Five mice per group were used, and the results are given as means ± SD for five mice. Statistical analysis was calculated by using the two-tailed Student's *t*-test. **P-values of ≤0.01) are considered as significant.

Abbreviations: MRSA, methicillin-resistant *Staphylococcus aureus*; SD, standard deviation.

Figure 4 Effect of FI-P_RP_RP_L-5 on inflammatory cytokines in MRSA skin lesions. Supernatants obtained from skin homogenates were used for the detection of TNF-α, IL-6, IL-1β and MCP-1 by ELISA.

Notes: Five mice per group were used, and the results are given as means ± SD for five mice. Statistical analysis was calculated by using the two-tailed Student's t-test. *P-values of ≤0.05 are considered significant; **P≤0.01 is considered as very significant.

Abbreviations: MRSA, methicillin-resistant *Staphylococcus aureus*; SD, standard deviation; TNF-α, tumor necrosis factor alpha; IL-6, interleukin-6; IL-1β, interleukin-1 beta; MCP-1, monocyte chemoattractant protein-1; ELISA, enzyme-linked immunosorbent assay.

bacterial count (95%) followed by 0.5% FI-P_RP_RP_L-5 (75%). These results suggest that topical application of 0.5% FI-P_RP_RP_L-5 exerts a positive effect on the wound healing process and reduces the bacterial load in MRSA-infected wounds.

FI-P_RP_RP_L-5 reduces inflammatory cytokines induced by MRSA infection

Excess inflammation, which is often associated with *S. aureus* skin infections, increases the clinical severity of the infection.⁴⁻⁶ Therefore, we tested the immunomodulatory properties of FI-P_RP_RP_L-5 in a mouse model of MRSA skin infection. The effect of FI-P_RP_RP_L-5 on levels of the inflammatory cytokines TNF-α, IL-6, IL-1β, and monocyte chemoattractant protein-1 was measured in the infected wounds using enzyme-linked immunosorbent assays. As shown in Figure 4, FI-P_RP_RP_L-5 (0.5%) significantly reduced the levels of TNF-α, IL-6, and IL-1β. In contrast, 2% mupirocin significantly reduced the level of only IL-6. These results indicate that, in addition to having potent antimicrobial activity, FI-P_RP_RP_L-5 has considerably higher anti-inflammatory properties than the traditional antimicrobial mupirocin.

Conclusion

In summary, we conclude that FI-P_RP_RP_L-5, a new antimicrobial peptide, possesses anti-staphylococcal and antibiofilm activities against multidrug-resistant clinical isolates of *S. aureus*. In addition, this peptide enhances wound closure and reduces bacterial load in MRSA-infected wounds. FI-P_RP_RP_L-5 reduced levels of the inflammatory cytokines TNF-α, IL-6, and IL-1β in wounds induced by MRSA infection. The anti-inflammatory properties of FI-P_RP_RP_L-5 might also have a beneficial effect on the healing of chronic and diabetic wounds.²³⁻²⁷ However, additional studies are needed to determine the exact mechanisms involved in the wound healing process. In conclusion, our study suggests that FI-P_RP_RP_L-5 might constitute a novel therapeutic option for the treatment of cutaneous staphylococcal skin infections. The current study also forms a strong platform for the further exploration of the immunomodulatory activities of antimicrobial peptides as part of a novel strategy for the treatment of staphylococcal skin infections.

Acknowledgments

The authors would like to thank the Network of Antimicrobial Resistance in *Staphylococcus aureus* (NARSA) program

supported under the US National Institute of Allergy and Infectious Diseases (NIAID)/ US National Institutes of Health (NIH) contract number HHSN272200700055C for providing MRSA strains used in this study.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Sen CK, Gordillo GM, Roy S, et al. Human skin wounds: a major and snowballing threat to public health and the economy. *Wound Repair Regen.* 2009;17(6):763–771.
2. Mohamed MF, Seleem MN. Efficacy of short novel antimicrobial and anti-inflammatory peptides in a mouse model of methicillin-resistant *Staphylococcus aureus* (MRSA) skin infection. *Drug Des Devel Ther.* 2014;8:1979–1983.
3. Sisirak M, Zvizdic A, Hukic M. Methicillin-resistant *Staphylococcus aureus* (MRSA) as a cause of nosocomial wound infections. *Bosn J Basic Med Sci.* 2010;10(1):32–37.
4. Guo S, Dipietro LA. Factors affecting wound healing. *J Dent Res.* 2010;89(3):219–229.
5. Montgomery CP, Daniels MD, Zhao F, Spellberg B, Chong AS, Daum RS. Local inflammation exacerbates the severity of *Staphylococcus aureus* skin infection. *PLoS One.* 2013;8(7):e69508.
6. Fournier B, Philpott DJ. Recognition of *Staphylococcus aureus* by the innate immune system. *Clin Microbiol Rev.* 2005;18(3):521–540.
7. del Rio A, Cervera C, Moreno A, Moreillon P, Miró JM. Patients at risk of complications of *Staphylococcus aureus* bloodstream infection. *Clin Infect Dis.* 2009;48 Suppl 4:S246–S253.
8. Keynan Y, Rubinstein E. *Staphylococcus aureus* bacteremia, risk factors, complications, and management. *Crit Care Clin.* 2013;29(3):547–562.
9. Mohamed MF, Hamed MI, Panitch A, Seleem MN. Targeting methicillin-resistant *Staphylococcus aureus* with short salt-resistant synthetic peptides. *Antimicrob Agents Chemother.* 2014;58(7):4113–4122.
10. McNeil JC, Hulten KG, Kaplan SL, Mason EO. Mupirocin resistance in *Staphylococcus aureus* causing recurrent skin and soft tissue infections in children. *Antimicrob Agents Chemother.* 2011;55(5):2431–2433.
11. Farrell DJ, Castanheira M, Chopra I. Characterization of global patterns and the genetics of fusidic acid resistance. *Clin Infect Dis.* 2011;52 Suppl 7:S487–S492.
12. Mohammad H, Thangamani S, Seleem MN. Antimicrobial peptides and peptidomimetics – potent therapeutic allies for staphylococcal infections. *Curr Pharm Des.* 2015;21(16):2073–2088.
13. Hancock RE, Sahl HG. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. *Nat Biotechnol.* 2006;24(12):1551–1557.
14. Kuriakose J, Hernandez-Gordillo V, Nepal M, et al. Targeting intracellular pathogenic bacteria with unnatural proline-rich peptides: coupling antibacterial activity with macrophage penetration. *Angew Chem Int Ed Engl.* 2013;52(37):9664–9667.
15. Nepal M, Thangamani S, Seleem MN, Chmielewski J. Targeting intracellular bacteria with an extended cationic amphiphilic polyproline helix. *Org Biomol Chem.* 2015;13(21):5930–5936.
16. Fillon YA, Anderson JP, Chmielewski J. Cell penetrating agents based on a polyproline helix scaffold. *J Am Chem Soc.* 2005;127(33):11798–117803.
17. Clinical and Laboratory Standards Institute. *Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard M7-A7.* CLSI, Wayne, PA. 2007.
18. Mohammad H, Mayhoub AS, Cushman M, Seleem MN. Anti-biofilm activity and synergism of novel thiazole compounds with glycopeptide antibiotics against multidrug-resistant staphylococci. *J Antibiot (Tokyo).* 2014;68(4):259–266.
19. O'Toole GA. Microtiter dish biofilm formation assay. *J Vis Exp.* 2011;47:2437.
20. Thangamani S, Younis W, Seleem MN. Repurposing ebselen for treatment of multidrug-resistant staphylococcal infections. *Sci Rep.* 2015;5:11596.
21. Rioja I, Bush KA, Buckton JB, Dickson MC, Life PF. Joint cytokine quantification in two rodent arthritis models: kinetics of expression, correlation of mRNA and protein levels and response to prednisolone treatment. *Clin Exp Immunol.* 2004;137(1):65–73.
22. King MD, Humphrey BJ, Wang YF, Kourbatova EV, Ray SM, Blumberg HM. Emergence of community-acquired methicillin-resistant *Staphylococcus aureus* USA 300 clone as the predominant cause of skin and soft-tissue infections. *Ann Intern Med.* 2006;144(5):309–317.
23. de la Fuente-Núñez C, Mansour SC, Wang Z, et al. Anti-biofilm and immunomodulatory activities of peptides that inhibit biofilms formed by pathogens isolated from cystic fibrosis patients. *Antibiotics (Basel).* 2014;3(4):509–526.
24. Wallace HJ, Stacey MC. Levels of tumor necrosis factor- α (TNF- α) and soluble TNF receptors in chronic venous leg ulcers – correlations to healing status. *J Invest Dermatol.* 1998;110(3):292–296.
25. Donath MY. Targeting inflammation in the treatment of type 2 diabetes: time to start. *Nat Rev Drug Discov.* 2014;13(6):465–476.
26. Jialal I, Miguelino E, Griffen SC, Devaraj S. Concomitant reduction of low-density lipoprotein-cholesterol and biomarkers of inflammation with low-dose simvastatin therapy in patients with type 1 diabetes. *J Clin Endocrinol Metab.* 2007;92(8):3136–3140.
27. Cowin AJ, Hatzirodos N, Rigden J, Fitridge R, Belford DA. Etanercept decreases tumor necrosis factor- α activity in chronic wound fluid. *Wound Repair Regen.* 2006;14(4):421–426.

Drug Design, Development and Therapy

Publish your work in this journal

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are a feature of the journal, which

Submit your manuscript here: <http://www.dovepress.com/drug-design-development-and-therapy-journal>

Dovepress

has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.